BRIXADI is indicated with the treatment of average to severe opioid use dysfunction in patients who may have initiated treatment with only one dose of a transmucosal buprenorphine item or who will be presently remaining handled with buprenorphine.At the time a brand-name drug’s patent has expired, a drug organization can file an “abbreviated ne